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Background: The pricing mechanism of orphan drugs appears arbitrary and has been referred to as a “black box”.
Therefore, the aim of this study is to investigate how drug- and disease-specific variables relate to orphan drug
prices. Additionally, we aim to explore if certain country-specific pricing and reimbursement policies affect the price
level of orphan drugs.
Methods: Annual treatment costs per indication per patient were calculated for 59 orphan drugs with a publicly
available price in Belgium, the Netherlands, Czech Republic, France, Italy and the United Kingdom. A multiple linear
regression model was built with 14 drug- and disease-specific variables. A Mann-Whitney U test was used to
explore whether there is a correlation between annual treatment costs of orphan drugs across countries with
different pricing and reimbursement policies.
Results: Repurposed orphan drugs, orally administered orphan drugs or orphan drugs for which an alternative
treatment is available are associated with lower annual treatment costs. Orphan drugs with multiple orphan
indications, for chronic treatments or for which an improvement in overall survival or quality-of-life has been
demonstrated, are associated with higher annual treatment costs. No association was found between annual
treatments cost of orphan drugs across countries and the different pricing and reimbursement systems.
Conclusions: This study has shown that prices of orphan drugs are influenced by factors such as the availability of
an alternative drug treatment, repurposing, etc. Current debate about the affordability of orphan drugs highlights the
need for more transparency in orphan drug price setting.
Keywords: Pricing, Price setting, Orphan drugsBackground
Recently, the price of some orphan drugs has become an
issue of much debate. For example, eculizumab, for the
treatment of paroxysmal nocturnal hemoglobinuria, can
cost up to US$ 500,000 per patient per year [1]. A few
orphan drugs even qualify as blockbusters, as their
global annual sales exceed a billion US$ [2]. Today,
third-party payers are increasingly cost-conscious and
concerned with escalating health care costs [1]. A Belgian
study showed that the impact of orphan drugs is substan-
tial (i.e. amounting to 1.9% of pharmaceutical expenditure
in 2008) and likely to rise significantly in the future [3].
An analysis by Schey et al. predicted that the expenditure
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unless otherwise stated.expenditure, is likely to plateau between four and five
percent [4]. Given current budgetary constraints and
concerns about affordability, it is likely that the price
and price setting of expensive medicines, such as orphan
drugs, will become the focus of attention.
Not much is known about the pricing of orphan drugs,
the pricing mechanism has even been referred to as a
“black box” [5,6]. Pricing of orphan drugs is unique
because R & D costs need to be recouped from a small
number of patients, also, orphan drugs benefit from a
period of market exclusivity and there are few alternatives
available [7]. Today, only a few descriptive studies have
identified a number of individual factors driving orphan
drug price setting. For example, an inverse correlation
between the price per capita of an orphan drug and the
prevalence of the indication has been reported in the
literature. The rarer the indication, the more expensive theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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complexity and therapeutic benefit have not been found
to correlate with the price of an orphan drug [6]. A recent
study regrouped orphan drugs in four categories, i.e. first-
to-market non-oncology orphan drugs, second-to-market
non-oncology orphan drugs, repurposed non-oncology
drugs and oncology orphan drugs. The annual weighted
treatment costs of drugs in the first category, accounting
for 44% of all orphan drugs, are in the highest range, with
an average cost of € 200,000 per patient per year. Mean
annual treatment costs of drugs in the other categories
range between €16,000 and €35,000 [9].
To the best of the authors’ knowledge, no recent studies
have investigated how annual treatment costs relate to
different drug-, disease- and country-specific variables. The
use of annual treatment costs has become an accepted
method to compare prices. For example, Messori et al. used
yearly cost per patient to define the inverse relation
between price and prevalence [8]. Orofino et al. calculated
mean annual treatment cost per patient to estimate
spending on orphan drugs in several European countries
[10]. Aballéa et al. found that low disease prevalence
and low number of available therapeutic alternatives
are associated with a higher annual treatment cost.
However, no significant association was found between
any other disease-related and drug-related variables and
yearly treatment cost, possibly due to a lack of power
[11]. Prices for orphan drugs also vary across countries
due to different pricing and reimbursement policies (e.g.
free vs. fixed pricing) [12]. Although national pricing
mechanisms are often not specific to orphan drugs, they
do tend to favor orphan drugs, for example, by setting up
special funds for reimbursement [5,13].
The aim of this study is to investigate how various drug-
and disease-specific variables relate to annual treatment
costs per patient and per orphan drug indication in six
European countries. Additionally, we aim to explore if
certain country-specific pricing and reimbursement policies
affect the price level of orphan drugs.
Methods
All orphan drugs, listed as authorized on the website of
the European Medicines Agency on April 17 2013 (n = 65)
and for which a price was publicly available in Belgium,
the Netherlands, Czech Republic, France, Italy or the
United Kingdom were included in the analysis [14].
Annual treatment dose
The annual treatment dose was calculated per indication
according to the standard treatment plan described in the
Summary of Product Characteristics (SmPC). If a starting
dose was adjusted based on (unknown) performance
results (e.g. for mecasermin (Increlex®)), the initial starting
dose was maintained. If a dose range was given (e.g. forromiplostim (Nplate®)), then an average dose between
the minimum and maximum dose was assumed. No
dose adjustments were carried out to account for liver
and/or kidney impaired patients. To determine the weight
or Body Surface Area (BSA) necessary to calculate the
dose of weight-adjusted and BSA-adjusted treatments,
weight and/or height information from pivotal studies as
described in the European Public Assessment Report
(EPAR) were consulted at first. Secondly, patient registries
(e.g. from the European Organisation for Research and
Treatment of Cancer) or relevant studies, as described on
clinicaltrials.gov or in publications were consulted. As a
last resort, weight and/or height data was derived from
standardized growth curves [15,16]. BSA was determined
using the Haycock formula, a validated method for calcu-
lating BSA in infants, children and adults [17]. The annual
treatment dose for children was calculated conservatively,
by assuming the lowest age (in accordance with the regis-
tered indication) and no weight and/or height increase
over the course of a year.
Treatment duration of 365 days was assumed, unless
stated differently in the SmPC. For treatments given in
cycles, the total number of cycles was based on the
treatment plan. In case of varying numbers of cycles,
the mean number of cycles in the main clinical study
(as described in the EPAR) was assumed. In case of
incatibant (Firazyr®), the number of cycles was calculated
based on the chance distributions described in the EPAR.
In the absence of data on the number of cycles, the
number of cycles was derived from the Overall Survival
(OS) time (e.g. for temsirolimus (Torisel®)).
Annual treatment cost
Orphan drug prices were analysed in six European coun-
tries (Belgium, the Netherlands, Czech Republic, France,
Italy and the United Kingdom), which were selected
based on public availability of orphan drug prices (Table 1).
Prices in Czech koruna (CZK) and British pound sterling
(GBP) were converted into Euro by applying the ex-
change rates of respectively €1 = 25.95 CZK (July 2013) and
€1 = 0.83 GBP (October 2013) [18]. The gross domestic
products (GDP) per capita in purchasing power standard
(PPS) of these countries are of similar magnitude, therefore
allowing international comparison (Table 1) [19]. The EU28
index equals 100 (standard deviation = 41.33) and varies
from 47 in Bulgaria to 263 in Luxemburg.
Annual treatment costs (ATX) were calculated per
patient per orphan drug indication and per country
based on the annual treatment dose and the most recent
price in each country. Vial wastage was assumed. If there
was an unfinished pack at the end of the year, only a pro-
portion of the price of that pack was accounted for. In
case of multiple packaging sizes, the cheapest pack (or
a combination of packs) was selected. Annual treatment
Table 1 Pricing data per country
GDP per
capita in PPS




Type of price* Distribution
channel [20]
Belgium 120 Belgian Centre for
Pharmacotherapeutic
Information
[21] 17/04/2013 41 Public prices Hospital pharmacies
Netherlands 128 College voor
Zorgverzekeringen






81 SÚKL State Institute
for Drug Control
[23] 29/07/2013 29 Rough prices for final
consumer
Hospital pharmacies













[27] 02/10/2013 50 Net cost Hospital pharmacies
GDP: gross domestic product, PPS: purchasing power standard, *type of prices: as described by data source: “public prices”, “consumer reimbursement prices”,
“rough prices for final consumer” and “maximum prices” represent ex-factory prices increased by a distribution margin for the wholesaler, a distribution margin for
the pharmacist, taxes and honoraria. “Ex-factory prices” and “net cost” are ex-factory prices without taxes and margins for distributers and pharmacists [28]. Due
to differences in margins, taxes and negotiations, pricing of orphan drugs may differ dependent on the distribution channel.
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were calculated separately. No official prices were found
for ivacaftor (Kalydeco®), alipogene tiparvovec (Glybera®),
concentrate of proteolytic enzymes enriched in bromelain
(NexoBrid®) and teduglutide (Revestive®) in any of the six
countries. Additionally, we were unable to calculate the
annual treatment cost for hydroxycarbamide (Siklos®)
and sapropterin dihydrochloride (Kuvan®) due to the
patient-specific nature of those treatments.
Statistical analysis
Table 2 provides an overview of the explanatory drug- and
disease-specific variables and the various data sources.
Drug-specific variables relate to an aspect of the drug
itself, (e.g. on the type of formulation), whereas disease-
specific variables describe aspects of the indication for
which the drug is used (e.g. the availability of an alter-
native treatment). Explanatory variables were selected
after a review of the literature. Relevant literature was
identified by searching the MEDLINE and Embase
databases. The following search terms and combinations
thereof were used: orphan drug, orphan medicinal prod-
uct, rare disease, rare disorder, cost, price, pricing, policies,
price-setting, market access, and budget. For practical
reasons, all selected articles were published in English,
French or Dutch. Bibliographies of relevant articles were
searched for additional references. Afterwards, variables
were selected based on the availability of data related to
each variable. For example, the literature indicates that
severity of the diseases could be related to price; however,
there is no reliable data available for rare diseases on
disease severity that can be used in a regression analysis
[1,5-8,10,29-36]. The common logarithms of the annualtreatment costs per country were considered the outcome
variables given that the original cost data were not normally
distributed. Firstly, a simple linear regression analysis was
performed in which all explanatory variables were indi-
vidually analysed to determine a linear relation with the
outcome variables. All explanatory variables, with a p-value
below 0.05 in the simple linear regression analysis, were
included in the multiple linear regression analysis. The
multiple linear regression models were reduced stepwise by
removing variables with significance levels above the 0.05
threshold. Variables with borderline significant p-values
were tolerated with a view to obtaining a higher coefficient
of determination (R2). All analyses were performed using
IBM SPSS Statistics version 22.
Additionally, the potential treatment population was
calculated per orphan drug, per country and at the EU28
level by multiplying the prevalence of the indication as
described in the European Public Assessment Report and/
or Orphanet website with recent population data from the
six countries and the EU28 as derived from Eurostat [19].
For orphan drugs with multiple indications, potential treat-
ment populations of separate indications were summarized.
Influence of country-specific pricing and reimbursement
policies
The independent samples Mann–Whitney U test was
used to explore whether there is an association between
annual treatment costs of orphan drugs across countries
with different pricing and reimbursement policies. The
Mann-Whitney U test determines whether the overall
distribution of annual treatment costs in one group (e.g.
in countries with free pricing) is greater or smaller than the
other (e.g. in countries with fixed pricing). Table 3 provides
Table 2 Regression model – explanatory variables
Variable Value Description and source
ONCO 0 or 1 Value 1 renders all oncology orphan drugs. Oncology orphan drugs were defined as ATC-class L
(Antineoplastic and immunomodulating agents).
YAUTH Continuous Number of years (as an integer number) since marketing authorization of the first indication by EMA.
AvailUS 0 or 1 Value 1 renders all orphan drugs with current authorization on the US market as listed by the FDA.
AvailUS is a proxy for size of the potential treatment population. [37]
MultipleIND 0 or 1 Value 1 renders all drugs with multiple orphan indications according to EMA. MultipleIND is a proxy
for size of the potential treatment population.
REPUR 0 or 1 Value 1 captures all repurposed drugs. [38]
QoLimp 0 or 1 Value 1 renders all drugs for which a statistically significant improvement in quality-of-life was described
in the European Public Assessment Report.
SurvImp 0 or 1 Value 1 captures all drugs for which a statistically significant improvement in survival was described in
the European Public Assessment Report.
dbRCT 0 or 1 Value 1 renders all drugs for which a double blind RCT was described in the European Public Assessment
Report. dbRCT is a proxy for strength of clinical trial evidence.
AltTx 0 or 1 Value 1 renders all drugs for which an alternative drug treatment is available. Supportive care, diet,
palliative care, transplantation and surgical procedures were not considered as an alternative.
ultrarare 0 or 1 Value 1 renders all drugs treating ultra-rare diseases. Ultra rare diseases have a prevalence of less than 2
per 100 000 as described in the European Public Assessment Report and/or Orphanet website.
chron 0 or 1 Value 1 renders all drugs for chronic (i.e.; longer than 6months) treatments.
oral 0 or 1 Value 1 captures all oral drugs.
Cosize 0 or 1 Cosize refers to the company size of the marketing authorization holder: respectively micro and small (0)
and medium and large (1) pharmaceutical companies. Company size is based on the European definition
described in EU recommendation 2003/361. Data on annual sales was derived from OneSource. [39]
Weightbased 0 or 1 Value 1 captures all drugs for which the annual treatment dose is dependent on the patient’s weight or
body surface area (BSA)
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market pharmaceutical pricing or price regulation (free
pricing may result in higher prices for drugs); a social
insurance or national health services reimbursement
system; the absence or presence of a Health Technology
Assessment (HTA) body; and the absence or presence
of cost-effectiveness criteria when assessing orphan drug re-
imbursement [5]. In countries with a low GDP, budgetary
restrictions can cause the exclusion of less cost-effective
orphan drugs [40-43].
Various countries apply innovative reimbursement mech-
anisms, so-called ‘managed entry agreements’ (MEAs),
to orphan drugs. The existence of a MEA has been doc-
umented for some orphan drugs in Belgium, England
and Wales, Italy and the Netherlands by Morel et al.
[44]. Therefore, a simple linear regression analysis wasTable 3 Pricing and reimbursement policies per country
Belgium France Netherlands
Pricing Price negotiations Price negotiations Price negotia
Reimbursement SI SI SI
HTA body ✓ ✓ ✓
Cost-effectiveness ✗ ✗ ✓
SI: Social insurance, NHS: National Health Service.performed to determine whether the existence of a MEA
for an orphan drug (0 – 1 variable) is associated with
higher or lower annual treatment costs in these countries.
Results
Simple linear regression
At significance threshold level 0.05, ten explanatory vari-
ables appeared to play a role in the price setting of orphan
drugs (Table 4). Orphan drugs which are also available
in the US (1), with multiple orphan indications (2), for
chronic treatments (3), for which an improvement in QoL
(4) or survival (5) has been demonstrated or for ultra-
rare indications (6) are correlated with higher annual
treatment costs. Orphan drugs for which an alternative
treatment is available (7), which are repurposed (8), which
are administered orally (9), or for which the marketCzech Republic Italy United Kingdom


















Variable (x) logBeATXcost= p-value logFrATXcost= p-value logNlATXcost= p-value logCzATXcost= p-value logItATXcost= p-value logUkATXcost= p-value
Cosize 4.422-0.214x 0.329 4.449-0.175x 0.360 4.033 + 0.258x 0.176 4.647-0.520x 0.015* 4.534-0.228x 0.477 4.505-0.115x 0.465
ONCO 4.290 + 0.007x 0.973 4.321 + 0.081x 0.677 4.000 + 0.313x 0.107 4.270 + 0.203x 0.361 4.573-0.326x 0.305 4.414 + 0.040x 0.804
YAUTH 4.584-0.042x 0.406 4.664-0.049x 0.220 4.396-0.044x 0.196 4.765-0.060x 0.267 4.519-0.006x 0.942 4.665-0.039x 0.204
AvailUS 3.837 + 0.600x 0.014* 3.829 + 0.661x 0.004* 3.967 + 0.242x 0.234 4.078 + 0.399x 0.104 3.973 + 0.543x 0.328 4.240 + 0.250x 0.189
MultipleIND 4.159 + 0.558x 0.024* 4.142 + 0.645x 0.001* 3.980 + 0.760x 0.001* 4.277 + 0.277x 0.241 4.277 + 0.595x 0.047* 4.292 + 0.455x 0.007*
REPUR 4.473-0.816x 0.001* 4.495-0.684x 0.003* 4.324-0.711x 0.000* 4.502-0.771x 0.006* 4.505-0.793x 0.303 4.558-0.545x 0.003*
QoLimp 4.239 + 0.451x 0.171 4.248 + 0.556x 0.019* 4.066 + 0.535x 0.069 4.313 + 0.427x 0.200 4.313 + 0.628x 0.052 4.368 + 0.348x 0.090*
Survimp 4.242 + 0.321x 0.274 4.344 + 0.069x 0.803 4.048 + 0.592x 0.031* 4.255 + 0.497x 0.057 4.424 + 0.350x 0.394 4.391 + 0.206x 0.303
dbRCT 4.341-0.089x 0.682 4.389-0.068x 0.724 4.265-0.278x 0.146 4.562-0.390x 0.074 4.435-0.085x 0.772 4.440-0.017x 0.915
altTX 5.000-0.883x 0.001* 4.919-0.782x 0.000* 4.471-0.436x 0.059 4.958-0.676x 0.039* 5.098-0.988x 0.000* 4.906-0.669x 0.000*
Ultrarare 4.200 + 0.303x 0.171 4.245 + 0.295x 0.132 4.132 + 0.163x 0.420 4.381 + 0.086x 0.752 4.281 + 0.353x 0.249 4.347 + 0.193x 0.249
Chronic 3.883 + 0.554x 0.021* 3.954 + 0.493x 0.040* 3.963 + 0.228x 0.289 4.310 + 0.073x 0.785 3.947 + 0.620x 0.124 4.114 + 0.414x 0.027*
Weightbased 4.185 + 0.216x 0.315 4.289 + 0.142x 0.458 4.231-0.209x 0.276 4.222 + 0.305x 0.167 4.346 + 0.351x 0.242 4.321 + 0.235x 0.143
Oral 4.563-0.500x 0.018* 4.609-0.449x 0.017* 4.154-0.040x 0.840 4.650-0.540x 0.012* 4.705-0.411x 0.156 4.623-0.400 0.011*
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sized pharmaceutical company (10) are associated with
lower annual treatment costs. The Spearman test for non-
parametric bivariate correlations showed a correlation
coefficient (rho) of −0.408 (2-sized p = 0.000) between
variables ‘ultra-rare indication’ and ‘alternative treatment’,
and a rho of 0.309 (p = 0.007) between ‘oral’ and ‘chronic’,
suggesting a mild correlation between these variables. Only
a strong correlation (|rho| > 0.7) between variables implies
that one of them should be omitted from the analysis.
Multiple linear regression
The multiple linear regression models showed, after
stepwise reduction, significant associations between in
total seven explanatory variables and the logarithm of
the average annual treatment costs in different coun-
tries (Table 5). Again, repurposed orphan drugs, orally
administered orphan drugs or orphan drugs for which
an alternative treatment is available are associated with
lower annual treatment costs. Orphan drugs with multiple
orphan indications, for chronic treatments or for which
an improvement in overall survival or QoL has been
demonstrated, are associated with higher annual treatment
costs. An average R2 of 0.674 was obtained, suggesting that
the variables above explain around 67.5% of the variability
in orphan drug annual treatment costs. Results from the
Czech and Italian regression model may be underpowered,
due to the smaller number of observations.
Finally, the independent samples Mann–Whitney U test
showed a significantly larger potential treatment popu-
lation (p = 0.034) in all countries and in the EU28 for
orphan drugs with multiple orphan indications compared
to orphan drugs with one orphan indication.
Influence of country-specific pricing and reimbursement
policies
No association was found between annual treatment cost
of orphan drugs across countries and the pricing system
(p = 0.209), the reimbursement system (p = 0.122), the
availability of an HTA body (p = 0.408) or the requirement
of cost-effectiveness at reimbursement (p = 0.791). Finally,
the simple linear regression analysis showed no significant
association between the annual treatment costs of orphan
drugs and the existence of MEAs for specific orphan drugs
in Belgium (p = 0.803), England and Wales (p = 0.215), Italy
(p = 0.805) and the Netherlands (p = 0.071).
Discussion
This study has identified various determinants of pricing
of orphan drugs. The multiple linear regression models
show significant associations between the average annual
treatment cost and seven explanatory variables. Further-
more, our results seem to suggest that there are no large
variations in orphan drug prices between countries in thisstudy, in spite of differences in pricing and reimbursement
policies. The annual treatment cost per patient of 18% of
orphan drugs in this study exceeds €100 000.
Firstly, orphan drugs with multiple orphan indications
are associated with higher prices. These results suggest
that the combined prevalence is not a determining factor
for price setting. Indeed, previous research showed that
orphan drug prices are determined based on the preva-
lence of the first indication [36,45]. Launch prices for
the first indication are unlikely to be reviewed following
approval in other indications [46]. We calculated that
orphan drugs with multiple indications have a significantly
larger potential market size, although it is essential to bear
in mind that no correct estimates of prevalence exist and
not all patients are diagnosed and/or treated [47]. As such,
the larger potential market size, combined with the higher
prices for these drugs, increase the likelihood of these
drugs becoming sufficiently profitable. The European
regulation provides a framework for the reduction of the
period of market exclusivity for orphan drugs which are
sufficiently profitable, but it has never been put into
practice [36,48]. There is growing concern about the
increasing prices of (orphan) drug treatments [49]. For
example, the median monthly price of anticancer drugs
increased from US$ 1,600 in the early 1990s, to more
than US$ 4,000 for anticancer drugs approved between
2000 and 2005 [50]. However, we could not confirm a
correlation between the price of orphan drugs and the
number of years since marketing authorization.
Secondly, repurposed orphan drugs are associated with
lower prices. Rollet et al. also showed that the average
annual treatment cost was the lowest for the category of
repurposed orphan drugs [9]. It was suggested that the
price of the initial common disease indication influences
the price of a repurposed orphan drug. In contrast, a
study in which Belgian hospital prices per defined daily
dose of the medicine for the common indication versus
the rare indication were compared, price differences of up
to 200-fold were reported. However, this study related
to a specific subset of repurposed drugs for which the
effectiveness evidence was already established prior to
the orphan designation [38].
Under the soon-to-be introduced value-based pricing
(VBP) system by NICE in the UK, all new medicines will
be priced according to their value. A study suggests that
diseases for which no other treatments are available rep-
resent an unmet need and should be prioritized under
the VBP system [51]. Indeed, unmet need (i.e. the absence
of alternative treatments), therapeutic benefit (i.e. QoL or
survival improvement) and therapeutic value (i.e. high
quality of clinical trial data, ease of administration) could
warrant high (er) prices. Our results show that the avail-
ability of an alternative drug treatment is associated
with lower prices for orphan drugs. In the past, only a
Table 5 Country-specific multiple linear regression models after stepwise reduction
Belgium
R2 = 0.739 n = 51
Constant = 4.734
France
R2 = 0.716 n = 59
Constant = 4.911
Netherlands
R2 = 0.570 n = 52
Constant = 4.170
Czech republic
R2 = 0.706 n = 41
Constant = 4.329
Italy
R2 = 0.656 n = 28
Constant = 5.098
United Kingdom
R2 = 0.661 n = 66
Constant = 4.652
Variable (x) Unstand. coeff. p-value Unstand. coeff. p-value Unstand. coeff. p-value Unstand. coeff. p-value Unstand. coeff. p-value Unstand. coeff. p-value
MultipleIND 0.504 0.001 0.570 0.010 0.312 0.028
Repurposed −0.573 0.006 −0.548 0.002 −0.557 0.005 −0.656 0.006 −0.325 0.039
altTx −0.478 0.026 −0.584 0.001 −0.988 0.000 −0.397 0.011
Oral −0.637 0.000 −0.328 0.023 −0.678 0.001 −0.392 0.006
Survimp 0.443 0.035
Chronic 0.464 0.025 0.445 0.044 0.296 0.089
ImprovQoL 0.565 0.021 0.509 0.060
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number of available alternatives for an orphan drug
and its price [11]. Also, orphan drugs for which an
improvement in survival and/or QoL has been demon-
strated, are associated with higher prices. Roos et al.
claim that the therapeutic benefit of an orphan drug
does not correlate with its price [6]. Due to difficulties in
generating evidence to demonstrate therapeutic benefit,
this information is often lacking or incomplete when the
price is set. We found no association between the exist-
ence of a double blind RCT and the price of an orphan
drug. A more in-depth analysis of clinical trial data is
required. From the patients’ point of view, the ease of
administration of an oral drug constitutes a considerable
therapeutic value as some intravenous or inhalation ther-
apies can be time-consuming. Our results correlate oral
orphan drugs with lower prices and chronic treatments
with higher prices. Popular media claimed that the most
expensive drugs are injectable drugs whose dosing varies
by weight [52]. Our results indicate that indeed, oral
orphan drugs are cheaper. However, we could not confirm
a correlation between weight-dependent dosing and price.
Finally, we found no correlation between different pricing
and reimbursement policies and the annual treatment cost
of orphan drugs across countries in this study. However, as
countries in this study likely have a similar ability to pay for
orphan drugs, we cannot conclude that there is a trend
towards uniform pricing of orphan drugs in Europe.
Additionally, many countries have special regulations
governing orphan drugs market [40]. For example, in
France, Italy and the Netherlands, there are specific policy
measures and incentives to promote research and devel-
opment of orphan drugs [20]. In England, some orphan
drugs are funded by the national Cancer Drug Fund from
the National Health Services [53]. In the Netherlands,
hospitals are financially supported for prescribing orphan
drugs through the Dutch Policy Rule for Expensive
Hospital and Orphan Drugs [54]. A differential pricing
system, in which price is dependent on a country’s
GDP, could enhance equal access to orphan drugs [29].
However, the success of differential pricing depends on
the ability to limit parallel export between countries [55].
Prices obtained after country-specific price negotiations or
in MEAs are not captured by this study. Higher prices for
orphan drugs do not increase the likelihood of a MEA.
This study provides insight into the interplay of orphan
drugs pricing and various drug and disease specific
explanatory variables. The variables in the multiple linear
regression models explain on average 67.5% of the variabil-
ity in orphan drug prices. The effects of each variable were
considered independently (i.e. no interactions between vari-
ables were added to the model), thereby reducing the risk
of overfitting. Due to the availability of data, we used a mix
of public prices and ex-factory prices, although resultstended to be consisted across countries. Final prices are
determined based on confidential negotiations with govern-
ments and are also influenced by rebates and discounts
negotiated with insurers, wholesalers and hospital phar-
macies [9]. Negotiated prices are confidential and are likely
to show more variability across countries. We were unable
to determine whether publicly available prices account
for rebates and/or are the result of negotiations. The
transformation of some variables to binary variables con-
stitute both a strength and a weakness, as it increases
the likelihood of obtaining significant results, but may
also oversimplify the analysis. Finally, annual treatment
dosages were calculated for “standard” patients without
accounting for lower adherence in daily life, lower dos-
ages for liver- and/or renal-impaired patients or other
patient-specific dose adjustments. Weights of patients
obtained from clinical trial data can possibly be skewed
due to the trial inclusion criteria.
Conclusion
This study has shown that prices of orphan drugs are
influenced by factors such as the availability of an alterna-
tive drug treatment, repurposing, the length of treatment,
the administration route, the presence of multiple indica-
tions and the impact on overall survival and QoL. Yet, a
lot of vagueness still surrounds the orphan drug pricing
mechanism. Current debate about the affordability of
high-priced orphan drugs and the impact on accessibility
highlights the need for more transparency around orphan
drug price setting. Within the context of value-based pri-
cing decisions, a Transparent Value Framework (TVF) has
been proposed with a set of indicative assessment criteria
[56]. The outcome of a TVF assessment could be included
as a factor in pricing negotiations. Unfortunately, country-
specific price negotiations may also add to the complexity
of orphan drug pricing.
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